With the conclusion of the ARVO Annual Meeting 2026, conversations across ophthalmology and eye banking are increasingly shifting toward the next phase of the industry's evolution. The research presented at ARVO was, as always, impressive. New preservation techniques, advances in endothelial cell assessment, and promising data on expanded donor eligibility criteria all generated significant interest.
But there is a growing recognition in the community that the next major breakthrough in eye banking outcomes will not come from research alone. It will come from the ability to operationalize research findings at scale — to implement new protocols consistently, across distributed teams, with the documentation and traceability that regulatory standards require.
The gap between what the science enables and what operations can consistently deliver is widening. Not because the teams are not capable, but because the systems supporting them were not built for the complexity and volume that modern eye banking demands. Manual workflows, disconnected tools, and paper-based documentation cannot scale with the demands being placed on the industry.
Closing this gap requires investment in operational infrastructure that matches the ambition of the clinical side of the field:
- Systems that can implement protocol changes consistently across all workflows
- Documentation tools that capture new assessment criteria without adding manual burden
- Real-time visibility that helps teams identify when new protocols are working — and when they need adjustment
- Traceability infrastructure that connects clinical decisions to downstream outcomes
The science is advancing. The operations need to keep pace. MidWire 20/20 is built to bridge that gap — giving eye banking teams the operational foundation they need to put the latest research into consistent, scalable practice.
